Literature DB >> 7585628

Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.

J M Glendening1, J F Flores, G J Walker, S Stone, A P Albino, J W Fountain.   

Abstract

Homozygous deletions of 9p21, including the cyclin-dependent kinase inhibitor genes p16INK4 and p15INK4B, have been reported frequently in melanoma (as well as other tumor) cell lines. Germline mutations within the p16INK4 gene have also been described in a proportion of familial melanoma kindreds, suggesting that p16INK4 is the 9p21 "melanoma" gene. We have previously concluded that deletion of this chromosomal region can occur early (before metastasis) and in vivo in sporadic melanoma due to the identification of identical hemizygous losses on 9p21 in six autologous melanoma cell lines established from an individual patient (DX). These related cell lines have now been used to evaluate the timing of deletion/mutation of the p16INK4 and p15INK4B genes during tumor progression in melanoma. Surprisingly, homozygous deletions of a < or = 200-kb region surrounding p15INK4B, but not p16INK4, were detected in all six cell lines. Furthermore, single strand conformation polymorphism and sequencing analysis of the remaining p16INK4 allele in each case revealed only one intragenic mutation (in DX-6), whereas Western analysis provided evidence that p16INK4 protein was expressed in all six instances. These findings, taken together with those generated on other unrelated melanoma tumors and cell lines, suggest that hemizygous loss (or haplo-insufficiency) of the p16INK4 gene may be enough to place a melanocyte on a tumor pathway, and/or that the p16INK4 gene is not the sole 9p21 locus targeted in sporadic melanoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585628

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

2.  p15 Expression Differentiates Nevus from Melanoma.

Authors:  Laura A Taylor; Conor O'Day; Tzvete Dentchev; Kyle Hood; Emily Y Chu; Todd W Ridky; John T Seykora
Journal:  Am J Pathol       Date:  2016-11-14       Impact factor: 4.307

3.  CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.

Authors:  Andrew S McNeal; Kevin Liu; Vihang Nakhate; Christopher A Natale; Elizabeth K Duperret; Brian C Capell; Tzvete Dentchev; Shelley L Berger; Meenhard Herlyn; John T Seykora; Todd W Ridky
Journal:  Cancer Discov       Date:  2015-07-16       Impact factor: 39.397

4.  Tumor suppressor INK4: refinement of p16INK4A structure and determination of p15INK4B structure by comparative modeling and NMR data.

Authors:  C Yuan; T L Selby; J Li; I J Byeon; M D Tsai
Journal:  Protein Sci       Date:  2000-06       Impact factor: 6.725

5.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

6.  Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis.

Authors:  E Latres; M Malumbres; R Sotillo; J Martín; S Ortega; J Martín-Caballero; J M Flores; C Cordón-Cardo; M Barbacid
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

7.  Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.

Authors:  L Chin; J Pomerantz; D Polsky; M Jacobson; C Cohen; C Cordon-Cardo; J W Horner; R A DePinho
Journal:  Genes Dev       Date:  1997-11-01       Impact factor: 11.361

Review 8.  Small round cell sarcomas.

Authors:  Florencia Cidre-Aranaz; Sarah Watson; James F Amatruda; Takuro Nakamura; Olivier Delattre; Enrique de Alava; Uta Dirksen; Thomas G P Grünewald
Journal:  Nat Rev Dis Primers       Date:  2022-10-06       Impact factor: 65.038

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.